Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zuclomifene - Veru Healthcare

Drug Profile

Zuclomifene - Veru Healthcare

Alternative Names: APP 944; cis-clomifene; cis-clomiphene citrate; RMI-16312; VERU-944; Zuclomiphene citrate

Latest Information Update: 07 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aspen Park Pharmaceuticals
  • Developer Veru Healthcare
  • Class Antineoplastics; Infertility therapies; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hot flashes

Most Recent Events

  • 07 Dec 2022 Zuclomifene is still in phase II trials for Hot flash in USA (Veru pipeline, December 2022)
  • 17 Feb 2022 Veru Healthcare plans a phase IIb trial for Hot flashes (in patients with advanced prostate cancer undergoing androgen deprivation therapy) (PO)
  • 19 Jun 2020 Veru, following an End of Phase 2 meeting, plans a phase III trial for Hot flashes (in patients with advanced prostate cancer) in late 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top